Ladenburg Thalmann Downgrades Viridian Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Michael Higgins has downgraded Viridian Therapeutics (NASDAQ:VRDN) from Buy to Neutral, indicating a change in the firm's outlook on the stock.
May 09, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Viridian Therapeutics was downgraded from Buy to Neutral by Ladenburg Thalmann, potentially impacting investor sentiment and the stock's short-term performance.
Analyst ratings often influence investor sentiment and can lead to short-term price movements. The downgrade from Buy to Neutral suggests a less optimistic outlook on VRDN by Ladenburg Thalmann, which could lead to decreased investor confidence and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100